EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

doi:10.1158/1078-0432.CCR-10-2666

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2011

Hu-Lieskovan Siwen, Vallbohmer Daniel, Zhang Wu, Yang Dongyun, Pohl Alexander, Labonte Melissa J, Grimminger Peter P, Hölscher Arnulf H, Semrau Robert, Arnold Dirk, Dellas Kathrin, Debucquoy Annelies, Haustermans Karin, Machiels Jean-Pascal H, Sempoux Christine, Rödel Claus, Bracko Matej, Velenik Vaneja, Lenz Heinz-Josef

Abstract excerpt

BACKGROUND: Cetuximab has shown significant clinical activity in metastatic colon cancer. However, cetuximab-containing neoadjuvant chemoradiation has not been shown to improve tumor response in locally advanced rectal cancer patients in recent phase I/II trials. We evaluated functional germline polymorphisms of genes involved in epidermal growth factor receptor pathway, angiogenesis, antibody-dependent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cetuximab

Share to Combined Modality Therapy

Share to Epidermal Growth Factor

Share to Neoadjuvant Therapy

Share to ras Proteins

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 21673069
DOI: 10.1158/1078-0432.CCR-10-2666
PMCID: PMC3149732

Genes

EGF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.PMID 21673069Read ↗

Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.Semantic proximity Read ↗

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.Semantic proximity Read ↗

The EGF 61A/G polymorphism - a predictive marker for recurrence of liver metastases from colorectal cancer.Semantic proximity Read ↗

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.Semantic proximity Read ↗

Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer.Semantic proximity Read ↗

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancerSemantic proximity Read ↗

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.Semantic proximity Read ↗

Prognostic Impact of Ras Mutation on Surgical Strategy in Rectal Cancer Patients Undergoing Neoadjuvant Treatment.Semantic proximity Read ↗

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Gene Polymorphisms Predict Pelvic Recurrence in Patients with Rectal Cancer Treated with ChemoradiationSemantic proximity Read ↗

Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.Semantic proximity Read ↗

XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.